Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2010
Athyros, V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Statins and heart failure.. J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  To switch (statins) or not to switch? That is the question.. Expert Opin Pharmacother. 11(18), 2943-6.
Anagnostis, P., Athyros V. G., Adamidou F., Florentin M., & Karagiannis A. (2010).  Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?. Curr Vasc Pharmacol. 8(5), 720-30.
2011
Katsiki, N., Mikhailidis D. P., Athyros V. G., & Karagiannis A. (2011).  Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.. Circ J. 75(8), 2027; author reply 2028.
Stavrinou, E., Koumaras C., Gossios T. D., Tziomalos K., Athyros V. G., & Karagiannis A. (2011).  Atherosclerotic renal artery stenosis: an update on diagnosis and management.. Curr Vasc Pharmacol. 9(4), 465-70.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 9(6), 698-705.
Anagnostis, P., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Impact of statins on glucose metabolism--a matter of debate.. Am J Cardiol. 107(12), 1866.
Athyros, V. G., Hatzitolios A. I., Karagiannis A., Savopoulos C., Katsiki N., Tziomalos K., et al. (2011).  IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.. Arch Med Sci. 7(6), 984-92.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Pagourelias, E. D., Gossios T. D., Tziomalos K., Karagiannis A., Geleris P., & Athyros V. G. (2011).  Residual cardiac risk reduction beyond lipid lowering.. Hellenic J Cardiol. 52(3), 197-203.
Athyros, V. G., Gossios T. D., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2011).  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Arch Med Sci. 7(6), 1067-75.
2012
Athyros, V. G., Gossios T. D., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.. Arch Med Sci. 8(1), 6-10.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.. J Clin Lipidol. 6(1), 93.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study.. Clin Appl Thromb Hemost. 18(1), 113-4.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.. Dig Dis Sci. 57(4), 1109.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές